Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA, LSD, DMT, mescaline and 2C-B as well as to receive 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc. Finally, the company announced the results of its first-ever survey on U.S. attitudes towards psychedelics. Conducted by the Harris Poll, the survey indicated that a majority of Americans who suffer from anxiety, depression, or PTSD feel that psychedelic medicine, including ketamine, psilocybin and MDMA, should be available. “Based on our survey results, the majority of affected Americans believe that psychedelic medicine should be made available to patients with treatment-resistant anxiety, depression or PTSD,” said Delic Holdings cofounder and CEO Matt Stang in the press release. “Our mission to make these new, science-backed medicines accessible and affordable to a greater number of people suffering from these conditions is more urgent than ever. The opening of the KWC Salt Lake City and Reno locations and the addition of FDA-approved SPRAVATO as a treatment option means we can serve more patients than any other ketamine provider in the U.S. With its latest Health Canada 56 exemptions, Delic Labs continues to lead the industry on the research of these novel psychedelic compounds and development of IP for future commercialization. Delic is opening doors to a future with more effective medicines for a variety of mental health conditions with longer lasting benefits and less side effects.”
To view the full press release, visit https://ibn.fm/FuApy
About Delic Holdings
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premier psychedelic wellness event; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and effective treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.